EPAS1 overexpression
|
GBM
|
EPAS1 overexpression
|
GBM
|
bevacizumab + erlotinib Resistant: C3 – Early Trials
|
bevacizumab + erlotinib Resistant: C3 – Early Trials
|
EPAS1 overexpression
|
Clear Cell Renal Cell Carcinoma
|
EPAS1 overexpression
|
Clear Cell Renal Cell Carcinoma
|
pazopanib Resistant: C3 – Early Trials
|
pazopanib Resistant: C3 – Early Trials
|
EPAS1 overexpression
|
HCC
|
EPAS1 overexpression
|
HCC
|
sorafenib Resistant: D – Preclinical
|
sorafenib Resistant: D – Preclinical
|